Resources from the same session
2211MO - Uncovering the mechanisms of persistent disease in RET-altered thyroid cancers: Insights from patient-derived xenograft models treated with selective RET inhibitors
Presenter: Alejandro Garcia Alvarez
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1183MO - Molecular characterization of rectal neuroendocrine tumors (NETs) with unfavorable prognosis by multiomics analysis: A multicenter retrospective cohort study (GARNET)
Presenter: Taro Shibuki
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1184MO - Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3): An AIO phase II study (EVINEC)
Presenter: Marianne Pavel
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1185MO - Activity and safety of avelumab alone or in combination with cabozantinib in patients with advanced high grade neuroendocrine neoplasias (NEN G3) progressing after chemotherapy. The phase II, open-label, multicenter AVENEC and CABOAVENEC trials
Presenter: Matthias M. Weber
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
725MO - Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: Focus on neuroendocrine carcinomas
Presenter: Valentina Gambardella
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 1184MO, 1185MO and 725MO
Presenter: Sara De Dosso
Session: Mini oral session - NETs and endocrine tumours
Resources:
Slides
Webcast
1186MO - A prospective phase II single-arm trial on neoadjuvant peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE followed by surgery for pancreatic neuroendocrine tumors (NeoLuPaNET)
Presenter: Stefano Partelli
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
2212MO - Major secondary outcomes in the multicentre noninferiority randomised trial IoN: Is ablative radioiodine necessary for low-risk differentiated thyroid cancer patients?
Presenter: Allan Hackshaw
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1187MO - Does the ENDOCAN-COMETE network improves the survival of adrenocortical carcinomas in France?
Presenter: Rossella Libe
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 1186MO, 2212MO and 1187MO
Presenter: Jaydira Del Rivero
Session: Mini oral session - NETs and endocrine tumours
Resources:
Slides
Webcast